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Introduction
Myoclonus-dystonia (MD) is a familial disorder with autosomal 
dominant inheritance. It is associated with a mutation of the 
ε-sarcoglycan gene (SGCE) and usually occurs during child-
hood. MD is a mixture of myoclonus and dystonia that mainly 
affects the proximal parts of the limbs and the trunk.1,2 About 
80% of patients with genetically confirmed MD respond dra-
matically to alcohol ingestion, but most respond poorly to medical 
treatment.1,2
We describe a female patient who developed MD in associ-
ation with an SGCE mutation. Both myoclonus and dystonia 
responded to anticholinergic treatment for 7 years and thereaf-
ter improved spontaneously.
Case Report
A 19-year-old girl visited our clinic due to generalized jerks and 
dystonia. Her birth, perinatal, growth, and development histories 
were unremarkable. She was a single child of nonconsanguin-
eous parents. Her 51-year-old father had experienced fine, 
jerky, postural tremor of both hands for 40 years, but the tremor 
did not disturb his activities of daily living. At the age of 5 
years, the patient’s parents noticed jerks of their daughter’s left 
foot. When she started to walk and run, she frequently fell due 
to twisting of the left foot. The jerks and dystonia progressively 
worsened up to the age of 13 years, spreading to involve the 
neck, trunk, and all four limbs. Thereafter, her symptoms stabi-
lized for the following 6 years. The jerks and dystonia were ag-
gravated by emotional stress and disappeared while she was 
sleeping. Her eye movements were normal. Detailed cognitive 
function tests revealed no abnormalities. She exhibited retro-
collis and backward and right-side tilting of the trunk as well 
as generalized jerks and dystonia that severely affected the left 
arm (Video Segment 1). Her left arm took a dystonic posture 
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BackgroundzzThe various medical treatments applied to myoclonus-dystonia patients with a mu-
tation of the ε-sarcoglycan gene (SGCE) have not been beneficial in most cases. Most patients ex-
perience progressive deterioration or static clinical courses, with only rare cases of spontaneous re-
mission.
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linergic treatment for 7 years and improved spontaneously.
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with flexion at the elbow, wrist, and metacarpophalangeal joints. 
She had no dysarthria or dysphagia. The dyskinesia improved 
markedly with the ingestion of small amounts of alcohol. Her 
motor and sensory function tests were normal. Deep-tendon 
reflexes were normoactive bilaterally, and plantar reflexes were 
flexor bilaterally. Cerebellar function tests were normal. Routine 
laboratory tests, measurements of serum ceruloplasmin, serum 
creatine kinase, and serum lactate levels were all normal. Her EEG, 
median somatosensory evoked potential studies, and brain MRI 
were normal. DNA analyses of the patient and her father show-
ed the same mutation in the SGCE gene [deletion in exon 6 
(c.771_772delAT, Cys258X)]. Genetic studies of the mutation of 
DTY1 and GCH-1 were negative. She did not respond to levodo-
pa/carbidopa (100/25 mg t.i.d.) or clonazepam (0.5 mg t.i.d.). Her 
dystonia and myoclonus responded markedly to trihexipheni-
dyl (2 mg t.i.d.). She stopped taking the medication many times, 
which resulted in recurrence of the dystonia and myoclonus. 
When trihexiphenidyl was discontinued at 7 years after the ini-
tiation of treatment (Video Segment 2), neither the myoclonus 
nor dystonia recurred, and the spontaneous remission persisted 
for more than 1year.
Discussion
The patient had some clinical features that are atypical for MD, 
such as dystonia starting from the distal part of the leg, markedly 
asymmetric myoclonus and dystonia, good response to low-
dose anticholinergic treatment, and spontaneous remission. 
However, her other clinical features (onset during childhood, 
dyskinesia consisting of dystonia and myoclonus, predominant 
involvement of the neck and trunk, and dramatic response to alco-
hol ingestion) were compatible with MD.1,2 The diagnosis was 
confirmed by a genetic study showing an SGCE mutation [de-
letion in exon 6 (c.771_772delAT, Cys258X)].2,3
The various medical treatments applied to MD patients have 
not been beneficial in most cases.1,2 Responsiveness to levodo-
pa has been described among reports of patients with geneti-
cally confirmed MD.2,4 In addition, some patients also benefit 
from anticholinergic drugs;1,2,4 however, they show a modest 
improvement that is frequently undermined by intolerable side 
effects. More favorable responses to anticholinergic treatment 
have been reported in several patients diagnosed with essential 
myoclonus or myoclonic dystonia, but their clinical diagnoses 
were not confirmed by genetic studies.5-7
Most patients with SGCE mutations exhibit progressive de-
terioration or static clinical courses. However, although spon-
taneous remission of dystonia may occur in about 20% of pa-
tients with MD during childhood or adolescence, the rate of 
spontaneous remission of myoclonus is only about 5%.2,3 In-
terestingly, our patient showed spontaneous remission of 
jerks and dystonia in her 20s. Therefore, although most patients 
with MD do not respond well to medical treatment, the pres-
ent case suggests that deep-brain stimulation should be delayed 
until patients are in their mid-20s.
Video Legends
Segment 1. A 19-year-old girl shows generalized jerks and dys-
tonia severely affecting the left arm. Her left arm takes a dys-
tonic posture with flexion at the elbow, wrist, and metacarpo-
phalangeal joints. She attempts to suppress the dyskinesia by put-
ting her left arm on her back. She also exhibits backward and 
right-side tilting of the trunk with retrocollis.
Segment 2. At the follow-up videotape recording performed 
at the age of 26 years, this patient exhibits marked spontane-
ous improvement of both the myoclonus and dystonia.
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